Analysts expect that Recro Pharma Inc (NASDAQ:REPH) will post $16.01 million in sales for the current quarter, according to Zacks Investment Research. Four analysts have provided estimates for Recro Pharma’s earnings. The lowest sales estimate is $15.65 million and the highest is $16.49 million. Recro Pharma reported sales of $19.04 million during the same quarter last year, which would suggest a negative year over year growth rate of 15.9%. The business is expected to announce its next earnings report on Tuesday, February 26th.
According to Zacks, analysts expect that Recro Pharma will report full-year sales of $75.42 million for the current financial year, with estimates ranging from $75.00 million to $76.05 million. For the next financial year, analysts expect that the company will post sales of $89.15 million, with estimates ranging from $76.90 million to $105.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that that provide coverage for Recro Pharma.
REPH has been the topic of a number of recent research reports. Zacks Investment Research raised shares of Recro Pharma from a “hold” rating to a “strong-buy” rating and set a $8.25 price target on the stock in a research report on Wednesday, November 7th. ValuEngine raised Recro Pharma from a “hold” rating to a “buy” rating in a research note on Tuesday, November 27th. Piper Jaffray Companies set a $10.00 target price on Recro Pharma and gave the company a “buy” rating in a research note on Thursday, November 8th. Oppenheimer set a $18.00 price target on Recro Pharma and gave the company a “buy” rating in a report on Thursday, November 8th. Finally, Janney Montgomery Scott reissued a “buy” rating and issued a $13.00 target price on shares of Recro Pharma in a research report on Thursday, January 31st. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the stock. Recro Pharma has a consensus rating of “Buy” and an average target price of $13.04.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. lifted its holdings in Recro Pharma by 27.6% during the 2nd quarter. BlackRock Inc. now owns 1,144,988 shares of the specialty pharmaceutical company’s stock worth $5,747,000 after buying an additional 247,559 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Recro Pharma by 5.2% during the second quarter. Renaissance Technologies LLC now owns 381,300 shares of the specialty pharmaceutical company’s stock worth $1,914,000 after purchasing an additional 18,700 shares in the last quarter. Northern Trust Corp increased its stake in Recro Pharma by 28.0% during the second quarter. Northern Trust Corp now owns 220,965 shares of the specialty pharmaceutical company’s stock valued at $1,109,000 after purchasing an additional 48,297 shares during the last quarter. Essex Investment Management Co. LLC grew its position in shares of Recro Pharma by 73.5% during the third quarter. Essex Investment Management Co. LLC now owns 252,874 shares of the specialty pharmaceutical company’s stock worth $1,798,000 after acquiring an additional 107,125 shares during the last quarter. Finally, Acadian Asset Management LLC lifted its holdings in Recro Pharma by 29.5% in the 3rd quarter. Acadian Asset Management LLC now owns 290,124 shares of the specialty pharmaceutical company’s stock valued at $2,063,000 after acquiring an additional 66,062 shares during the last quarter. 52.11% of the stock is owned by institutional investors.
Shares of NASDAQ:REPH opened at $8.55 on Thursday. The firm has a market cap of $186.85 million, a P/E ratio of -4.30 and a beta of -0.31. The company has a quick ratio of 1.16, a current ratio of 1.36 and a debt-to-equity ratio of 4.04. Recro Pharma has a 1-year low of $4.78 and a 1-year high of $13.05.
Recro Pharma Company Profile
Recro Pharma, Inc, a specialty pharmaceutical company, engages in developing non-opioid products for the treatment of acute pain primarily in the United States. The company's lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.